Can Low LSD Doses Address Alzheimer’s Disease?
Eleusis Is Investigating Anti-Inflammatory Properties Of Psychedelics
The CEO of Eleusis tells Scrip how the privately held biotech plans to progress low-dose lysergic acid diethylamide (LSD) to both prevent and treat Alzheimer’s
